Abstract
Pancreatic cancer constitutes one of the most aggressive tumours with a 5-year survival rate of less than 5%. It is characterized by a high degree of resistance to apoptosis which is associated by high expression levels of multiple prosurvival proteins of the extrinsic and intrinsic apoptosis signalling cascades. This review focuses on current knowledge of apoptotic pathways involved in pancreatic cancer and mechanisms of resistance to apoptosis, including alterations in the death receptor and mitochondrial pathways, as well as anti-apoptotic effects of NF-kB and Akt signalling and the impact of histon-modifying enzymes such as histondeacetylases (HDAC). Furthermore, the therapeutic implications of modulating pro-survival pathways by specific inhibitors investigated in preclinical and clinical trials will be discussed.
Keywords: Pancreatic cancer, apoptosis, therapeutic targets, extrinsic pathway, intrinsic pathway, HDAC, NF-kB, Akt, tumor stroma, apoptosis, pancreatic cancer, mechanisms of resistance
Current Pharmaceutical Biotechnology
Title:Therapeutic Targeting of Apoptotic Pathways: Novel Aspects in Pancreatic Cancer
Volume: 13 Issue: 11
Author(s): A. Neesse, T.M. Gress and P. Michl
Affiliation:
Keywords: Pancreatic cancer, apoptosis, therapeutic targets, extrinsic pathway, intrinsic pathway, HDAC, NF-kB, Akt, tumor stroma, apoptosis, pancreatic cancer, mechanisms of resistance
Abstract: Pancreatic cancer constitutes one of the most aggressive tumours with a 5-year survival rate of less than 5%. It is characterized by a high degree of resistance to apoptosis which is associated by high expression levels of multiple prosurvival proteins of the extrinsic and intrinsic apoptosis signalling cascades. This review focuses on current knowledge of apoptotic pathways involved in pancreatic cancer and mechanisms of resistance to apoptosis, including alterations in the death receptor and mitochondrial pathways, as well as anti-apoptotic effects of NF-kB and Akt signalling and the impact of histon-modifying enzymes such as histondeacetylases (HDAC). Furthermore, the therapeutic implications of modulating pro-survival pathways by specific inhibitors investigated in preclinical and clinical trials will be discussed.
Export Options
About this article
Cite this article as:
Neesse A., Gress T.M. and Michl P., Therapeutic Targeting of Apoptotic Pathways: Novel Aspects in Pancreatic Cancer, Current Pharmaceutical Biotechnology 2012; 13 (11) . https://dx.doi.org/10.2174/138920112802501953
DOI https://dx.doi.org/10.2174/138920112802501953 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Intraoperative Magnetic Resonance Imaging
Current Medical Imaging Gender Hormones: Role in the Pathogenesis of Central Nervous System Disease and Demyelination
Current Neurovascular Research Engineered Inorganic/Organic-Core/Shell Magnetic Fe<sub>x</sub>O<sub>y</sub> Nanoparticles with Oleic Acid and/or Oleylamine As Capping Agents
Current Pharmaceutical Design Epigenetic and Disease Targets by Polyphenols
Current Pharmaceutical Design Inhibiting Breast Cancer Progression by Exploiting TGFβ Signaling
Current Drug Targets Nano-Neurotherapeutics (NNTs): An Emergent and Multifaceted Tool for CNS Disorders
Current Drug Metabolism Targeting Brain Tumors with Nanomedicines: Overcoming Blood Brain Barrier Challenges
Current Clinical Pharmacology Mutagenic Approaches to Modifying Gap Junction Phenotype
Current Drug Targets Refractory Angina Pectoris: Lessons from the Past and Current Perspectives
Current Pharmaceutical Design How Recent Advances in High-risk Myelodysplastic Syndrome Physiopathology May Impact Future Treatments
Current Pharmaceutical Design Evaluation of Non-Coding RNAs as Potential Targets in Head and Neck Squamous Cell Carcinoma Cancer Stem Cells
Current Drug Targets Emerging Role of Circular RNAs in Kidney Diseases in Nephrology
Current Drug Targets Adenovirus Vector Production and Purification
Current Gene Therapy Third Generation Antipsychotic Drugs: Partial Agonism or Receptor Functional Selectivity?
Current Pharmaceutical Design Regulation of Hypoxia-inducible Factor-1α and Vascular Endothelial Growth Factor Signaling by Plant Flavonoids
Mini-Reviews in Medicinal Chemistry Inhibitors of the Microsomal Prostaglandin E2 Synthase-1 as Alternative to Non Steroidal Anti-Inflammatory Drugs (NSAIDs) – A Critical Review
Current Medicinal Chemistry Synthesis and Evaluation of <sup>198</sup>Au/PAMAM-MPEG-FA against Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry TGF-ß / Smad Signaling in Prostate Cancer
Current Drug Targets Recent Trends of Biocompatible and Biodegradable Nanoparticles in Drug Delivery: A Review
Current Medicinal Chemistry Evaluation of Venom as a Promising Tool for Drug Discovery: Focusing on Neurological Disorders
Venoms and Toxins